Canon Medical Systems has launched a new variant of its Aplio i900 Premium Cardiovascular Ultrasound for structural heart disease after obtaining clearance from the US Food and Drug Administration (FDA).
Part of the firm’s Aplio i-series platform, the new system is designed to provide cardiologists and cardiovascular sonographers with easy access to new 4D imaging features such as 4D TEE transcatheter procedure guidance with quantitative technologies.
These technologies include Mitral Valve Analysis (MVA) which offers rapid valve analysis during planning, implantation and post-op evaluation.
The system is also said to feature automated analysis and measurement tools called Ejection Fraction with Global Longitudinal Strain, Myocardial Performance Index (MPI) and 3D Wall Motion Tracking to aid in detecting early stage cardiac disease and quantifying cardiac function.
Powered by iPerformance, the newly added capabilities of the device are expected to facilitate high imaging clarity and definition for fast and reliable diagnoses.
Canon Medical Systems USA Ultrasound business unit director Dan Skyba said: “The Aplio i900 offers healthcare providers a complete solution that delivers diagnostic confidence for a wide range of cardiovascular imaging needs, including adult, paediatric, foetal echo, stress echo and transesophageal echocardiography.
“The enhanced 2D and 4D visualisation made available on this new system empowers cardiologists to conduct complex cardiac imaging exams, while continuing to utilise a cost-effective, less invasive and safer tool than other traditional imaging modalities.”
The new Aplio i900 also includes iSense and touch-control screens to deliver intuitive ergonomics and real-time quick scan for automatic image adjustments.